Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising developments in Voyager Therapeutics’ Alzheimer’s portfolio and their innovative ALPL NeuroShuttle platform. During a recent investment conference, the company’s management highlighted preclinical data demonstrating the NeuroShuttle’s ability to maintain CNS exposure significantly longer than competing technologies, suggesting a potential safety advantage. This advancement, along with the strategic sequencing of their Alzheimer’s programs, enhances Voyager’s platform and positions it well for future partnerships.
Additionally, Voyager’s VY7523, an anti-tau antibody, is progressing through Phase 1 trials with promising initial data expected in 2026. The unique binding properties of VY7523 and its selection based on preclinical efficacy underscore its potential. Furthermore, the VY1706 tau-silencing gene therapy is on track for regulatory filings in 2026, leveraging Voyager’s TRACER capsid platform to achieve significant reductions in tau messenger RNA and protein levels in preclinical studies. These developments collectively support the Buy rating and the $30 price target set by Trucchio.
According to TipRanks, Trucchio is a 5-star analyst with an average return of 13.6% and a 47.23% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and COMPASS Pathways.
In another report released on September 2, Citi also assigned a Buy rating to the stock with a $11.00 price target.